VINC vs. ASMB, SLS, PMVP, CMRX, MRNS, IOBT, ONCY, HOOK, MIST, and CUE
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Assembly Biosciences (ASMB), SELLAS Life Sciences Group (SLS), PMV Pharmaceuticals (PMVP), Chimerix (CMRX), Marinus Pharmaceuticals (MRNS), IO Biotech (IOBT), Oncolytics Biotech (ONCY), Hookipa Pharma (HOOK), Milestone Pharmaceuticals (MIST), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical preparations" industry.
Vincerx Pharma (NASDAQ:VINC) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.
Vincerx Pharma has higher earnings, but lower revenue than Assembly Biosciences.
Assembly Biosciences' return on equity of -120.58% beat Vincerx Pharma's return on equity.
44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 22.9% of Vincerx Pharma shares are held by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Vincerx Pharma currently has a consensus target price of $5.00, indicating a potential upside of 602.25%. Given Vincerx Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Vincerx Pharma is more favorable than Assembly Biosciences.
Vincerx Pharma has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
In the previous week, Assembly Biosciences had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 1 mentions for Assembly Biosciences and 0 mentions for Vincerx Pharma. Assembly Biosciences' average media sentiment score of 1.92 beat Vincerx Pharma's score of 0.00 indicating that Assembly Biosciences is being referred to more favorably in the news media.
Assembly Biosciences received 222 more outperform votes than Vincerx Pharma when rated by MarketBeat users. However, 64.52% of users gave Vincerx Pharma an outperform vote while only 59.31% of users gave Assembly Biosciences an outperform vote.
Summary
Vincerx Pharma beats Assembly Biosciences on 8 of the 14 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
